InstantWhyThe numbers
CNBC reports that Pfizer posted quarterly results above Wall Street estimates and raised the low end of its full-year revenue guidance, driven by strength in its non-Covid product portfolio. The company cut its full-year revenue expectation for Covid products to $4 billion, down from around $5 billion previously. Pfizer has not yet independently confirmed the results.
Why it matters
Raising guidance while simultaneously lowering Covid expectations by a billion dollars shows the rest of the business is performing well enough to more than offset that decline. The shift marks progress in Pfizer's effort to prove it can grow without relying on vaccines and antivirals that drove record sales in 2021 and 2022.
How this compares
Pfizer last reported earnings on August 4, when it beat on both profit and revenue as investors assessed its drug portfolio recovery, according to our prior coverage. The company has faced sustained scrutiny over dividend sustainability and its pipeline of new products. Rival Merck recently raised its revenue outlook on new drug sales, though it cut profit guidance due to an acquisition charge tied to its Terns Pharmaceuticals deal.
What to watch
The raised guidance floor suggests management has growing confidence in its non-Covid franchise for the remainder of the year. Investors will look for detail on which specific drugs are driving the outperformance and whether the momentum can continue as Covid product sales continue their decline.
- ✓Detected and written at 2026-08-04 11:24
- ✓First reported by CNBC
- ✓Written from public facts in our own words — never a copy
- ✓Published as fast as possible; our team holds editorial responsibility
Sources
- CNBC — Top News: https://www.cnbc.com/2026/08/04/pfizer-pfe-earnings-q2-2026.html
More stories
InstantWhyHut 8 misses estimates as revenue reaches $74.9 million in Q2
InstantWhyGriffon Corp files 8-K disclosing deal completion, new agreement and additional material events
InstantWhy